MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in ...

There is major uncertainty regarding research funding now, and while usage trends for PacBio's systems are good, the reality is that these are expensive machines and this is not a good time to be ...

Earnings Call Insights: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems ...

PacBio’s earnings surpassed the Zacks Consensus ... it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor ...

With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. The life sciences tools and services sector supports the research, development, and commercialization of biotechnology ...

University of Washington & UDN Research: Demonstrated PacBio’s ability to simultaneously analyze the genome, methylome, epigenome, and transcriptome, providing novel insights into a rare and ...

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation ...

20:11 EST Cathie Wood’s ARK Investment bought 344K shares of PacBio (PACB) today Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51 ...

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...